Polymorphism (-499C/G) in DDAH2 promoter may act as a protective factor for metabolic syndrome: A case-control study in Azar-Cohort population

• Published in: Archives of Endocrinology and Metabolism Vol. 65; no. 4; pp. 443 - 449
• Main Authors: Faramarzi, Elnaz, Aftabi, Younes, Ansarin, Khalil, Somi, Mohammad Hossein, Gilani, Neda, Seyedrezazadeh, Ensiyeh
• Format: Journal Article
• Language: English
• Published: Brazil Sociedade Brasileira de Endocrinologia e Metabologia 03-11-2021; Brazilian Society of Endocrinology and Metabolism
• Subjects: Amidohydrolases - genetics; Case-Control Studies; cohort study; DDAH2; Female; Genetic Predisposition to Disease - genetics; Genotype; Humans; Male; metabolic syndrome; Metabolic Syndrome - genetics; Original; polymorphism; Polymorphism, Genetic; Polymorphism, Single Nucleotide - genetics; Promoter Regions, Genetic; Protective Factors; rs805305; metabolic syndrome; polymorphism; cohort study; rs805305; DDAH2
• ISSN: 2359-3997; 2359-4292
• DOI: 10.20945/2359-3997000000391

Globally developing metabolic syndrome (MetS) prevalence as a major health problem can be related to multiple factors of genetic and environmental. Dimethylaminohydrolase 2 (DDAH2) is the main enzyme implicated in the cardiovascular system, which regulates the nitric oxide pathway. This study investigated the association of
polymorphism -499C/G (rs805305) with the risk of MetS among the Azar-Cohort population.
The occurrence of SNP rs805305 in the
gene was tested using the PCR-RFLP method in 332 MetS cases and 294 healthy controls. Afterward, the association of the allele and genotypes with the risk of MetS and its components were examined.
The G allele and GC genotype were significantly associated with a reduced risk of MetS (
≤ 0.001). Also, the dominant genetic model (GG+GC) significantly decreased the risk of MetS (
= 0.001), however, in sex subtypes MetS risk was significantly reduced in males before and in females after adjustment for age (
≤ 0.02).
The -499C/G polymorphism of
may play a protective role and reduce MetS risk among the Azar-Cohort population.